Prevention of type 1 diabetes

Endocrinology and Metabolism Clinics of North America
Diane K Wherrett, D Daneman

Abstract

Prevention of loss of beta cells in type 1 diabetes is a major goal of current research. Knowledge of the genetic susceptibility, increasing ability to predict who may be at risk, recognition of the potential clinical impact of residual insulin secretion after diagnosis, and development of new immunomodulatory agents have supported an increasing number of clinical trials to prevent beta-cell loss. Interventions can be targeted at 3 stages: before the development of autoimmunity (primary prevention), after autoimmunity is recognized (secondary prevention), or after diagnosis when significant numbers of beta cells remain (tertiary prevention). Thus far, several agents show promise when given shortly after diagnosis, but no interventions before diagnosis have shown benefit. Knowledge in this area has grown quickly in recent years and will continue to grow rapidly with several international collaborative efforts underway.

References

Sep 8, 1988·The New England Journal of Medicine·J SilversteinS Johnson
Jul 24, 1986·The New England Journal of Medicine·H Yki-Järvinen, V A Koivisto
Mar 12, 1994·BMJ : British Medical Journal·E von MutiusH H Thiemann
Oct 31, 1998·Diabetic Medicine : a Journal of the British Diabetic Association·R BonfantiEzio Bonifacio
Aug 24, 2000·The New England Journal of Medicine·T M BallA L Wright
Jul 31, 2001·Lancet·M A Atkinson, George S Eisenbarth
May 29, 2002·Diabetologia·Edwin A M Gale
May 31, 2002·The New England Journal of Medicine·Diabetes Prevention Trial--Type 1 Diabetes Study Group
May 31, 2002·The New England Journal of Medicine·Kevan C HeroldJeffrey A Bluestone
Jul 11, 2002·Diabetologia·M J Redondo, George S Eisenbarth
Jul 13, 2002·American Journal of Medical Genetics·Hans K AkerblomMikael Knip
Oct 2, 2003·JAMA : the Journal of the American Medical Association·Jill M NorrisMarian Rewers
Mar 27, 2004·Lancet·Edwin A M GaleEuropean Nicotinamide Diabetes Intervention Trial (ENDIT) Group
Mar 27, 2004·BMJ : British Medical Journal·Devasenan DevendraGeorge S Eisenbarth
Jan 22, 2005·Diabetic Medicine : a Journal of the British Diabetic Association·D Daneman
Jan 22, 2005·Diabetic Medicine : a Journal of the British Diabetic Association·P BettsT Wilkin
Jun 7, 2005·Diabetes Research and Clinical Practice·P PozzilliIMDIAB group
Jun 24, 2005·The New England Journal of Medicine·Bart KeymeulenLucienne Chatenoud
Nov 25, 2005·Diabetes·Peter AchenbachAnette-G Ziegler
Jun 7, 2007·Pediatric Diabetes·TRIGR Study Group
Jul 21, 2007·Nature Reviews. Immunology·Lucienne Chatenoud, Jeffrey A Bluestone
Sep 27, 2007·JAMA : the Journal of the American Medical Association·Jill M NorrisMarian Rewers
Oct 19, 2007·Proceedings of the National Academy of Sciences of the United States of America·Janet M WenzlauJohn C Hutton
Jan 22, 2008·The Journal of Allergy and Clinical Immunology·Marc C Levesque, E William St Clair
Oct 1, 2008·Pediatric Diabetes·Jeffrey L MahonType 1 Diabetes TrialNet Study Group
Oct 10, 2008·The New England Journal of Medicine·Johnny LudvigssonRosaura Casas
Dec 23, 2008·Diabetes Research and Clinical Practice·Tony R Merriman
Jan 28, 2009·Nature Reviews. Immunology·J Rodrigo MoraUlrich H von Andrian

Citations

Jul 26, 2011·Clinical & Developmental Immunology·Brett PhillipsNick Giannoukakis
May 22, 2013·Journal of Diabetes Research·Brian G PierceJohn P Mordes
Jan 6, 2016·The British Journal of Radiology·Huseyin ToprakYaşar Cesur
Oct 30, 2015·Diabetes, Obesity & Metabolism·T WilkinRory McCrimmon
Feb 19, 2016·Expert Opinion on Drug Metabolism & Toxicology·Alberto VerrottiPasquale Parisi
Aug 15, 2015·Journal of Diabetes Research·Aldo Ferreira-HermosilloVictoria Mendoza
Oct 27, 2018·Mini Reviews in Medicinal Chemistry·Amro Mohamed SolimanSrijit Das
Mar 1, 2020·Medicinal Research Reviews·Selena Le BaggeJosephine M Forbes

Related Concepts

Diabetes, Autoimmune
Impacts, Environmental
Islets of Langerhans
Remission Induction
Autoimmune Diseases
Clinical Trials
Diabetes Mellitus, Insulin-Dependent
Disease Susceptibility
Structure of Beta Cell of Islet
Primary Prevention

Related Feeds

Autoimmune Diabetes & Tolerance

Patients with type I diabetes lack insulin-producing beta cells due to the loss of immunological tolerance and autoimmune disease. Discover the latest research on targeting tolerance to prevent diabetes.

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.

Related Papers

Chemistry & Biology
Kira Weissman
The Journal of Immunology : Official Journal of the American Association of Immunologists
Kai W Wucherpfennig
© 2021 Meta ULC. All rights reserved